Loading...
Loading...
Analysts at Leerink Swann initiated coverage on
ACADIA Pharmaceuticals Inc. ACAD with a Outperform rating.
The target price for ACADIA Pharmaceuticals is set to $48.
ACADIA Pharmaceuticals shares have gained 92.90% over the past 52 weeks, while the S&P 500 index has surged 12.97% in the same period.
ACADIA Pharmaceuticals shares rose 1.33% to $38.00 in pre-market trading.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in